[go: up one dir, main page]

WO1999056698A3 - Traitement de la maladie caeliaque - Google Patents

Traitement de la maladie caeliaque Download PDF

Info

Publication number
WO1999056698A3
WO1999056698A3 PCT/DK1999/000255 DK9900255W WO9956698A3 WO 1999056698 A3 WO1999056698 A3 WO 1999056698A3 DK 9900255 W DK9900255 W DK 9900255W WO 9956698 A3 WO9956698 A3 WO 9956698A3
Authority
WO
WIPO (PCT)
Prior art keywords
interfering
deamidation
celiac disease
glutamine residue
gliadin
Prior art date
Application number
PCT/DK1999/000255
Other languages
English (en)
Other versions
WO1999056698A2 (fr
Inventor
Hans Sjoestroem
Ove Noren
Original Assignee
Univ Koebenhavn
Hans Sjoestroem
Ove Noren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Koebenhavn, Hans Sjoestroem, Ove Noren filed Critical Univ Koebenhavn
Priority to AU35961/99A priority Critical patent/AU3596199A/en
Priority to EP99917810A priority patent/EP1075267A2/fr
Publication of WO1999056698A2 publication Critical patent/WO1999056698A2/fr
Publication of WO1999056698A3 publication Critical patent/WO1999056698A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/12—Magnesium silicate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne une méthode de traitement de la maladie caeliaque, qui consiste à contrecarrer la déamidation d'au moins un reste glutamine dans une molécule de gliadine ou de gluténine. Pour ce faire, on peut inhiber ou contrecarrer la déamidation d'au moins un reste glutamine, par la dérivation d'au moins un reste glutamine, par la dérivation d'au moins un reste glutamine dans une molécule de gliadine ou de gluténine de farine de blé, par déamidation chimique ou enzymatique du gluten, suivie de la dérivation chimique ou enzymatique du(des) groupe(s) carboxyle(s) généré(s). L'invention porte aussi sur une méthode permettant de contrecarrer la déamidation d'au moins un reste glutamine dans une molécule de gliadine ou de gluténine et donc de traiter la maladie caeliaque. Ledit procédé consiste à administrer, à un patient atteint d'une maladie caeliaque ou suspecté d'en être atteint, au moins une des substances suivantes: (a) une substance capable d'augmenter le pH dans le tractus gastroduodénal d'un sujet, par exemple un antacidum, un agent anticholinergique, des antagonistes du récepteur H2 ou un inhibiteur de la pompe à protons; (b) une substance capable d'éliminer la déamidation de bactéries dans le tractus gastroduodénal d'un sujet, par exemple un agent antibiotique ou antimicrobien; et/ou (c) une substance capable de contrecarrer l'effet d'au moins une enzyme de déamidation dans le tractus gastroduodénal d'un sujet.
PCT/DK1999/000255 1998-05-06 1999-05-06 Traitement de la maladie caeliaque WO1999056698A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU35961/99A AU3596199A (en) 1998-05-06 1999-05-06 Treatment of celiac disease
EP99917810A EP1075267A2 (fr) 1998-05-06 1999-05-06 Traitement de la maladie caeliaque

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DK62198 1998-05-06
DK0621/98 1998-05-06
US9154598P 1998-07-01 1998-07-01
US60/091,545 1998-07-01

Publications (2)

Publication Number Publication Date
WO1999056698A2 WO1999056698A2 (fr) 1999-11-11
WO1999056698A3 true WO1999056698A3 (fr) 1999-12-29

Family

ID=26064330

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1999/000255 WO1999056698A2 (fr) 1998-05-06 1999-05-06 Traitement de la maladie caeliaque

Country Status (3)

Country Link
EP (1) EP1075267A2 (fr)
AU (1) AU3596199A (fr)
WO (1) WO1999056698A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348495B1 (en) 1996-06-06 2002-02-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Method for treating celiac disease
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
WO2001002389A1 (fr) 1999-06-30 2001-01-11 Takeda Chemical Industries, Ltd. Cristaux de composes benzimidazole
DK1572127T4 (da) 2002-02-14 2014-11-24 Univ Leland Stanford Junior Enzymbehandling af fødevarer til cøliaki
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US8697094B2 (en) 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations
AU2003294473A1 (en) * 2002-11-20 2004-06-15 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
AU2011247868B2 (en) * 2004-04-28 2014-05-22 Btg International Limited Epitopes related to coeliac disease
ITMI20062080A1 (it) * 2006-10-30 2008-04-30 Consiglio Nazionale Ricerche Trattamento di farine di cereali per il consumo alimentare da parte di pazienti celiaci
CA2680590C (fr) 2007-03-16 2017-10-17 Jonathan David Gass Therapie enzymatique de combinaison pour la digestion de gluten dietetique
KR20100123758A (ko) 2008-03-10 2010-11-24 다케다 야쿠힌 고교 가부시키가이샤 벤즈이미다졸 화합물의 결정
AU2012207267C1 (en) * 2011-01-20 2017-11-23 Cyrex Laboratories, Llc Methods and apparatus for detection of gluten sensitivity, and its differentiation from celiac disease
US20140037661A1 (en) * 2011-02-08 2014-02-06 Phadia Ab Wheat Antigens and Peptides for Diagnosis of Wheat Induced Hypersensitivity
ITSR20130002A1 (it) 2013-10-08 2015-04-08 Danilo Ciciulla Nuovo processo industriale di lavorazione per la produzione di alimenti farinacei, destinati a soggetti con malattia celiaca clinicamente manifesta, a base di farine comuni.
WO2017089961A1 (fr) * 2015-11-24 2017-06-01 Universidade De Trás-Os-Montes E Alto Douro Procédé de production de farines de céréales et de protéines enrichies en l-théanine, et produits respectifs
CN105434459A (zh) * 2015-12-25 2016-03-30 南阳医学高等专科学校 一种治疗溃疡的西药配方及其制备工艺
IT201800010305A1 (it) 2018-11-13 2020-05-13 Danilo Ciciulla Procedimento per la preparazione di alimenti a base di farina di grano destinati a soggetti celiaci o affetti da gluten sensitivity

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338334A (en) * 1977-12-29 1982-07-06 Merck & Co., Inc. 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases
EP0278174A2 (fr) * 1986-12-24 1988-08-17 Glaxo Group Limited Emploi de fluticasone propionate pour la préparation d'un médicament pour le traitement de troubles intestinaux
DD262999A1 (de) * 1987-07-27 1988-12-21 Adw Ddr Verfahren zur herstellung eines diaetetikums fuer zoeliakie- und spruekranke
SU1581315A1 (ru) * 1987-12-07 1990-07-30 Пятигорский научно-исследовательский институт курортологии и физиотерапии Способ лечени целиакии у детей
EP0444829A2 (fr) * 1990-02-27 1991-09-04 FISONS plc Composés immunosupressifs
WO1992018524A1 (fr) * 1991-04-17 1992-10-29 Prodotti Chimici E Alimentari S.P.A. Acides n-alkyl-tauroursodesoxycholiques, leurs derives therapeutiquement actifs, leur procede de preparation et compositions pharmaceutiques les contenant
WO1998003872A2 (fr) * 1996-07-18 1998-01-29 Detlef Schuppan Procede immunologique de mise en evidence d'anticorps diriges contre la transglutaminase tissulaire (ttg), utilisation de la ttg a des fins de diagnostic et de controle de therapie et agent pharmaceutique oral contenant de la ttg

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338334A (en) * 1977-12-29 1982-07-06 Merck & Co., Inc. 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases
EP0278174A2 (fr) * 1986-12-24 1988-08-17 Glaxo Group Limited Emploi de fluticasone propionate pour la préparation d'un médicament pour le traitement de troubles intestinaux
DD262999A1 (de) * 1987-07-27 1988-12-21 Adw Ddr Verfahren zur herstellung eines diaetetikums fuer zoeliakie- und spruekranke
SU1581315A1 (ru) * 1987-12-07 1990-07-30 Пятигорский научно-исследовательский институт курортологии и физиотерапии Способ лечени целиакии у детей
EP0444829A2 (fr) * 1990-02-27 1991-09-04 FISONS plc Composés immunosupressifs
WO1992018524A1 (fr) * 1991-04-17 1992-10-29 Prodotti Chimici E Alimentari S.P.A. Acides n-alkyl-tauroursodesoxycholiques, leurs derives therapeutiquement actifs, leur procede de preparation et compositions pharmaceutiques les contenant
WO1998003872A2 (fr) * 1996-07-18 1998-01-29 Detlef Schuppan Procede immunologique de mise en evidence d'anticorps diriges contre la transglutaminase tissulaire (ttg), utilisation de la ttg a des fins de diagnostic et de controle de therapie et agent pharmaceutique oral contenant de la ttg

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
BRUCE, S. E. ET AL: "Human jejunal transglutaminase: demonstration of activity, enzyme kinetics and substrate specificity with special relation to gliadin and celiac disease", CLIN. SCI. (1985), 68(5), 573-9 CODEN: CSCIAE;ISSN: 0143-5221, XP002085949 *
DATABASE WPI Section Ch Week 199113, Derwent World Patents Index; Class B06, AN 1991-092939, XP002118955 *
DE MAGALHAES A.F.N. ET AL: "[The use of antibiotics in digestive tract diseases]. USO DE ANTIBIOTICOS EM DOENCAS DO APARELHO DIGESTIVO.", REVISTA BRASILEIRA DE CLINICA E TERAPEUTICA, (1979) 8/11 (505-516). CODEN: RBCTAP, XP002118952 *
FREEMAN H.J.: "Ranitidine -associated interstitial nephritis in a patient with celiac sprue.", CAN. J. GASTROENTEROL., (1988) 2/1 (35-36). ISSN: 0835-7900 CODEN: CJGAEJ, Canada, XP002085955 *
FRIIS S U: "COELIAC DISEASE. PATHOGENESIS AND CLINICAL ASPECTS", APMIS, vol. 104, no. SUPPL. 61, 1 January 1996 (1996-01-01), pages 5 - 48, XP000605982, ISSN: 0903-4641 *
GRAHAM D Y ET AL: "Mechanism of increase in steatorrhea with calcium and magnesium in exocrine pancreatic insufficiency: an animal model.", GASTROENTEROLOGY, (1982 SEP) 83 (3) 638-44. JOURNAL CODE: FH3. ISSN: 0016-5085., United States, XP002085956 *
GRAHAM D Y: "Pancreatic enzyme replacement: the effect of antacids or cimetidine.", DIGESTIVE DISEASES AND SCIENCES, (1982 JUN) 27 (6) 485-90. JOURNAL CODE: EAD. ISSN: 0163-2116., United States, XP002085957 *
JOURET A. ET AL: "[Digestive pathologies and intraepithelial lymphocytes]. PATHOLOGIE DIGESTIVE ET LYMPHOCYTES INTRA-EPITHELIAUX.", ACTA ENDOSCOPICA, (1995) 25/5 SUPPL. (563-569). ISSN: 0240-642X CODEN: AENDD5, France, XP002085954 *
KASPER H ET AL: "[Therapy of diseases of the small intestine]. Die Therapie von Dunndarmerkrankungen.", MEDIZINISCHE WELT, (1969 DEC 20) 51 2777-9. JOURNAL CODE: MIM. ISSN: 0025-8512., GERMANY, WEST: Germany, Federal Republic of, XP002085953 *
MEHTA D.I. ET AL: "Chronic diarrhea: Causes, presentation, and management.", INDIAN JOURNAL OF PEDIATRICS, (1996) 63/4 (459-471). ISSN: 0019-5456 CODEN: IJPEA2, India, XP002085951 *
MOLBERG, OYBIND ET AL: "Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease", NAT. MED. (N. Y.) (1998), 4(6), 713-717 CODEN: NAMEFI;ISSN: 1078-8956, XP002085952 *
SOLLID L M ET AL: "Autoantibodies in coeliac disease: tissue transglutaminase --guilt by association?.", GUT, (1997 DEC) 41 (6) 851-2., XP002118953 *
UHLIG, H. ET AL: "Role of tissue transglutaminase in gliadin binding to reticular extracellular matrix and relation to coeliac disease autoantibodies", AUTOIMMUNITY (1998), 28(4), 185-195, XP002118954 *
UNSWORTH J ET AL: "Flat small intestinal mucosa and autoantibodies against the gut epithelium.", JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, (1982) 1 (4) 503-13. JOURNAL CODE: JL6. ISSN: 0277-2116., United States, XP002085950 *

Also Published As

Publication number Publication date
EP1075267A2 (fr) 2001-02-14
WO1999056698A2 (fr) 1999-11-11
AU3596199A (en) 1999-11-23

Similar Documents

Publication Publication Date Title
WO1999056698A3 (fr) Traitement de la maladie caeliaque
NZ595193A (en) Modified Proteases That Inhibit Complement Activation
EP2308963A3 (fr) Systèmes pour le traitement des cellules obtenues par liposuccion
CA2514036A1 (fr) Conception de catheter facilitant le positionnement sur un tissu a diagnostiquer ou a traiter
WO2001052847A8 (fr) Composes thiazole, imidazole et oxazole et traitements de troubles associes au vieillissement des proteines
EP1693073A3 (fr) Pansements contenant des hydrogels hydratés et des enzymes
WO2007079169A3 (fr) Traitement pour une leucémie myéloïde aiguë
ATE242003T1 (de) Enzyme zur behandlung von diabetes mellitus typ i
WO2001066553A3 (fr) Nouveaux inhibiteurs de la fructose-1,6-biophosphatase, a base d'aryle
WO2005048926A3 (fr) Methodes pour traiter la douleur
WO2022008971A3 (fr) Traitement d'une infection à coronavirus associé au syndrome respiratoire aigu sévère avec klotho
TR199802441A2 (xx) Kanda a��r� �rik asit bulunmas�n�n tedavisi ve �nlenmesi i�in y�ntem ve terkip.
WO2003045910A3 (fr) Diagnostic des troubles endotheliaux a l'aide de l'indice de bioactivite de l'oxyde nitrique
WO2006044556A3 (fr) Methodes de traitement du diabete
WO2003030886A3 (fr) Allylamides utilises dans le traitement de la maladie d'alzheimer
WO2002090925A3 (fr) Polypeptides acides nucleiques associes au cancer
WO2005060960A3 (fr) Utilisation de l'histamine pour le traitement de maladies osseuses
WO2005020970A3 (fr) Compositions d'inhibiteurs de proteases pour prevenir et traiter des problemes de la peau
SE0401631L (sv) Ny sammansättning
WO2002059611A3 (fr) Diagnostic et traitement du cancer a l'aide de polypeptides et de polynucleotides pellino de mammifere
WO2005112987A3 (fr) Procede de preparation et d'utilisation d'enzymes fibrinolytiques pour le traitement d'une maladie
Cimerman et al. Characterization of cystatin C from bovine parotid glands: cysteine proteinase inhibition and antiviral properties
WO2003103699A8 (fr) Utilisation de ramoplanine pour traiter des troubles associes a la prise d'antibiotiques
WO2000039290A8 (fr) Formulation pharmaceutique contenant un enzyme decomposant l'acide hyaluronique et d'origine microbienne
WO2003047421A3 (fr) Methodes et reactifs pour le diagnostic et le traitement du diabete

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 09705743

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1999917810

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999917810

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999917810

Country of ref document: EP